Chronic Myeloid Leukemia

Common Name(s)

Chronic Myeloid Leukemia

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Chronic Myeloid Leukemia" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Chronic Myeloid Leukemia" returned 1383 free, full-text research articles on human participants. First 3 results:

[Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].
 

Author(s): Juan Enrique Santos-MacĂ­as, Enrique Baez de la Fuente, Arnoldo Salas-Delgado

Journal: Gac Med Mex. ;152(3):334-8.

 

Chronic myeloid leukemia is a myeloproliferative disease characterized by the Philadelphia chromosome and with this, the chimeric protein BCR-ABL. The first-line treatment is imatinib, a tyrosine kinase inhibitor, that has showed good results, but with a significant percentage of ...

Last Updated: 23 Jun 2016

Go To URL
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
 

Author(s): Kazuma Ohyashiki, Tomohiro Umezu, Seiichiro Katagiri, Chiaki Kobayashi, Kenko Azuma, Tetsuzo Tauchi, Seiichi Okabe, Yutaka Fukuoka, Junko H Ohyashiki

Journal:

 

Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM)). To determine a possible biomarker for STOP-IM CML, we examined plasma miRNA expression ...

Last Updated: 20 Apr 2016

Go To URL
Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
 

Author(s): Juan Liu, Yujing Zhang, Aichun Liu, Jinghua Wang, Lianqiao Li, Xi Chen, Xinyu Gao, Yanming Xue, Xiaomin Zhang, Yao Liu

Journal:

 

Although dasatinib is effective in most imatinib mesylate (IMT)-resistant chronic myeloid leukemia (CML) patients, the underlying mechanism of its effectiveness in eliminating imatinib-resistant cells is only partially understood. This study investigated the effects of dasatinib on ...

Last Updated: 13 Apr 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Chronic Myeloid Leukemia" returned 159 free, full-text review articles on human participants. First 3 results:

Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.
 

Author(s): Katsushi Takebayashi, Hiromichi Sonoda, Tomoharu Shimizu, Hiroyuki Ohta, Hitoshi Minamiguchi, Mitsuaki Ishida, Eiji Mekata, Yoshihiro Endo, Tohru Tani, Masaji Tani

Journal:

 

Pyomyositis is a rare, subacute, deep pyogenic infection of the muscle tissue. This disease has been previously described in patients that were immunocompromised due to a hematological malignancy.

Last Updated: 20 Apr 2016

Go To URL
The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
 

Author(s): Priyanka A Pophali, Mrinal M Patnaik

Journal: Cancer J. ;22(1):40-50.

 

Imatinib mesylate was the first tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia. Imatinib produces acceptable responses in approximately 60% of patients, with approximately 20% discontinuing therapy because of intolerance and approximately 20% ...

Last Updated: 4 Feb 2016

Go To URL
Chronic myeloid leukemia: First-line drug of choice.
 

Author(s): Elias Jabbour

Journal: Am. J. Hematol.. 2016 Jan;91(1):59-66.

 

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has been considered the standard of care for more than a decade. Second generation compounds, namely dasatinib ...

Last Updated: 15 Jan 2016

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Bosutinib in Elderly Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 21 Nov 2016

Go to URL
Regional Central Database Recording of Chronic Myeloid Leukemia
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 16 Aug 2016

Go to URL
Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
 

Status: Recruiting

Condition Summary: Chronic Myeloid Leukemia

 

Last Updated: 15 Sep 2016

Go to URL